CTOs on the Move

Transcend Health

www.transcend.healthcare

 
Transcend Health is a healthcare company that provides a digital health platform for first responders, encompassing health, physical fitness, training, and wellness. They also offer a Direct Primary Care model for employers to provide superior access t...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Capitol Drugs

Capitol Drugs is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sherman Oaks, CA. To find more information about Capitol Drugs, please visit www.capitoldrugs.com

LMA North America

LMA North America is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nikon Instruments

Nikon Instruments is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phreesia

Leading healthcare organizations choose Phreesia to revolutionize their point of service. In medical groups of all sizes, Phreesia`s flexible and scalable platform drives tangible results across administrative, financial and clinical operations so that staff can focus on providing exceptional patient care.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.